Patents by Inventor Kristin Lundy DeMello

Kristin Lundy DeMello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-heteroatom-substituted pyrazoles
    Patent number: 6894067
    Abstract: The present invention relates to 5-heteroatom-substituted pyrazoles of the formula I: wherein the ring of the formula (R5)-A-(SOmR4), m, B, R1 through R5 are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: May 17, 2005
    Assignee: Pfizer, Inc.
    Inventors: Martha L. Minich, Subas M. Sakya, Andrei Shavnya, Kristin Lundy DeMello
  • Selective inhibitors of cyclooxygenase-2
    Patent number: 6846818
    Abstract: The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: pharmaceutical compositions containing them, to their medicinal use, and to their preparations. The compounds of the invention are particularly useful in the treatment or alleviation of inflammation and inflammation associated disorders, such as, for example, rheumatoid arthritis and osteoarthritis, and in the relief of pain, such as, for example, pain associated with surgery or trauma, in mammals, preferably felines and canines.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: January 25, 2005
    Assignee: Pfizer Inc.
    Inventors: Kristin Lundy DeMello, Brian S. Bronk, Rhonda Marie Crosson
  • COX-2 selective carprofen for treating pain and inflammation in dogs
    Publication number: 20030212123
    Abstract: Treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (COX-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (COX-1) by selectively inhibiting COX-2 activity with reference to COX-1 activity, wherein the selectivity ratio or COX-2:COX-1 activity inhibition is at least 3:1 based on ex vivo inhibition levels measured in whole blood; the inhibitor is a member selected from the group of anti-inflammatory compounds consisting essentially of salicylic acid derivatives, p-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)(S)-enantiomer of 6-chloro-&agr;-methyl-9H-carbazole-2-acetic acid.
    Type: Application
    Filed: April 24, 2003
    Publication date: November 13, 2003
    Applicant: Pfizer Inc.
    Inventors: Kristin Lundy DeMello, Anthony P. Ricketts
  • Selective inhibitors of cyclooxygenase-2
    Publication number: 20030207897
    Abstract: The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: 1
    Type: Application
    Filed: April 16, 2003
    Publication date: November 6, 2003
    Applicant: Pfizer Inc.
    Inventors: Kristin Lundy DeMello, Brian S. Bronk, Rhonda Marie Crosson
  • 5-Heteroatom-substituted pyrazoles
    Publication number: 20030134858
    Abstract: The present invention relates to 5-heteroatom-substituted pyrazoles of the formula I: 1
    Type: Application
    Filed: November 1, 2002
    Publication date: July 17, 2003
    Inventors: Martha L. Minich, Subas M. Sakya, Andrei Shavnya, Kristin Lundy DeMello